SV

Street Verdict

Analyst Scorecard

ABBOTINDIA · NSE

Abbott India Limited

₹26,525

+3.23% (+₹830)

Prev. close

₹25,695

Volume

11,142

Delivery %

52.3%

As of

20 Nov 2026

Price history

₹26,525-₹55 (-0.21%) · 3M
18 Aug 2026 → 20 Nov 2026
25,50026,00026,50027,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Abbott India Limited

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Kartik Rajendran

Headquarters

Mumbai

Employees

3,679

Key stats

Market cap

₹57,628.11 Cr

P/E ratio (TTM)

35.7

Dividend yield

2.03%

EPS (TTM)

₹759.86

Beta (1Y · daily vs NIFTY 50)

0.25

Beta (5Y · monthly vs NIFTY 50)

0.07

Shares float

51.93 L

EPS · quarter ended Jun 2026

₹201.66

Financial Performance

01 · Financials

0 Cr2500 Cr5000 Cr7500 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0250500750₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0250500750₹0%100%200%300%28 Aug 2019 Jul 2102 Aug 2221 Jul 2319 Jul 2425 Jul 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-25%0%25%50%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr2500 Cr5000 Cr7500 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr500 Cr1000 Cr1500 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹4,996.48 Cr₹5,502.88 Cr₹6,097.18 Cr₹6,684.73 Cr₹7,217.19 Cr
₹3,916.75 Cr₹4,229.06 Cr₹4,479.43 Cr₹4,797.78 Cr₹5,137.92 Cr
PROFIT BEFORE TAX
₹1,079.73 Cr₹1,273.82 Cr₹1,617.75 Cr₹1,886.95 Cr₹2,079.27 Cr
₹281.03 Cr₹324.41 Cr₹416.53 Cr₹472.51 Cr₹527.25 Cr
₹801.62 Cr₹953.03 Cr₹1,201.24 Cr₹1,409.02 Cr₹1,551.17 Cr
PROFIT FOR THE YEAR
₹798.70 Cr₹949.41 Cr₹1,201.22 Cr₹1,414.44 Cr₹1,552.02 Cr
₹2.92 Cr₹3.62 Cr₹2.00 L₹-5.42 Cr₹-85.00 L
Basic and Diluted - (Face value of " 10 each)
375.86446.78565.28665.62730.36

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,840.45 Cr₹4,224.12 Cr₹4,555.51 Cr₹5,193.49 Cr₹5,917.31 Cr₹6,501.93 Cr
₹3,840.45 Cr₹4,224.12 Cr₹4,555.51 Cr₹5,193.49 Cr₹5,917.31 Cr₹6,501.93 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: standalone statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹-85.56 Cr₹106.96 Cr₹52.07 Cr₹268.85 Cr₹-118.26 Cr
₹947.66 Cr₹893.39 Cr₹1,212.81 Cr₹1,011.84 Cr₹1,319.24 Cr
₹-395.84 Cr₹-147.71 Cr₹-416.03 Cr₹182.18 Cr₹-371.38 Cr
₹-637.38 Cr₹-638.72 Cr₹-744.71 Cr₹-925.17 Cr₹-1,066.12 Cr
Cash and cash equivalents at the beginning of the year
₹218.27 Cr₹132.71 Cr₹239.67 Cr₹291.74 Cr₹560.59 Cr
Cash and cash equivalents at the end of the year (Refer Note 10)
₹132.71 Cr₹239.67 Cr₹291.74 Cr₹560.59 Cr₹442.33 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Abbott India Limited₹54,823.20 Cr₹27,12034.011.4832.5%0.04+8.1%-7.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

ABBOTINDIA

Abbott India Q2 FY27 EBITDA Climbs to Rs. 568 Cr

Abbott India reported Q2 FY27 operating EBITDA of Rs 568 crore, up from Rs 502 crore a year earlier, and revenue from operations surpassed Rs 1,951 crore, an 11.03% YoY increase. Net profit rose 9.19% to Rs 453.45 crore, reflecting strong domestic demand and cost discipline, supporting its position in the Indian pharmaceutical market.

ABBOTINDIA

Abbott India dividend exceeds half-year operating cash flow

Multibagg AI · 17 days ago